Clinical trials: in Philippines
Non Small Cell Lung Cancer
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib
- Trial name
- NCT00364351
- Testing
- Vandetanib, Erlotinib
- Where
- 153 sites in United States, Argentina and 20 more
- Volunteers
- 1,574 people
- Sponsor
- Genzyme, a Sanofi Company
Asthma
Asthma Exacerbation Study
This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.
- Trial name
- NCT01086384
- Testing
- Fluticasone Furoate/GW642444, Fluticasone furoate
- Where
- 183 sites in United States, Argentina and 9 more
- Volunteers
- 2,020 people
- Sponsor
- GlaxoSmithKline
Asthma
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
- Trial name
- NCT00398645
- Testing
- GW685698X 200mcg,GW685698X 200mcg and 400mcg
- Where
- 82 sites in United States, Australia and 14 more
- Volunteers
- 648 people
- Sponsor
- GlaxoSmithKline
Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
This multi-center, open-label, randomized study will evaluate the participant preference with subcutaneous versus intravenous administration of MabThera/Rituxan (rituximab) in participants with CD20+ diffuse large B-cell lymphoma…
- Trial name
- NCT01724021
- Testing
- Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP), Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP), Bendamustine
- Where
- 246 sites in Argentina, Australia and 30 more
- Volunteers
- 743 people
- Sponsor
- Hoffmann-La Roche
Volunteers
Voclosporin in Healthy Japanese Volunteers
The study is a single-centre, double-blind, placebo controlled, randomized, ascending multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamic profiles of voclosporin.
- Trial name
- NCT02949999
- Testing
- Voclosporin
- Where
- Philippines
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aurinia Pharmaceuticals Inc.
Dengue Fever, Fever
Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia
The purpose of this study is to detect acute febrile episodes and dengue infection in five Asian countries, to assess dengue seroprevalence, and to assess surveillance infrastructure at investigational sites in anticipation of a…
- Trial name
- NCT01218906
- Where
- 11 sites in Indonesia, Malaysia and 3 more
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Sanofi
Lupus Erythematosus, Systemic
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
This is a multi-center, double-blind, randomized, Phase 2b trial to evaluate the efficacy of atacicept in subjects with systemic lupus erythematosus (SLE).
- Trial name
- ADDRESS II (NCT01972568)
- Testing
- Atacicept 75 milligram (mg), Atacicept 150 mg
- Where
- 138 sites in United States, Argentina and 16 more
- Volunteers
- 306 people
- Sponsor
- EMD Serono
Bipolar I Depression
Lurasidone Pediatric Bipolar Study
A study to evaluate efficacy and safety of flexibly dosed Lurasidone in children and adolescents with bipolar I depression
- Trial name
- Illuminate (NCT02046369)
- Testing
- Lurasidone
- Where
- 66 sites in United States, Bulgaria and 9 more
- Volunteers
- 350 people
- Sponsor
- Sumitomo Pharma America, Inc.
Pulmonary Embolism, Thromboembolism
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of…
- Conditions
- Pulmonary Embolism, Thromboembolism, Thrombosis, Venous Thrombosis
- Trial name
- EinsteinChoice (NCT02064439)
- Testing
- BAY 59-7939, ASA
- Where
- 266 sites in United States, Australia and 29 more
- Volunteers
- 3,365 people
- Sponsor
- Bayer
Encephalitis, Japanese Encephalitis
Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers
This is a long-term follow-up of the persistence of immune response in participants who previously received a single dose of JE-CV at age 12 to 18 months in Study JEC02 (NCT00735644) .
- Trial name
- NCT01001988
- Testing
- Blood sample, JE-CV administered in Study JEC02
- Where
- 4 sites in Philippines, Thailand
- Volunteers
- 596 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Alzheimer's Disease
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers
This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed either AVA102670 or AVA102672.
- Trial name
- NCT00490568
- Testing
- Rosiglitazone XR
- Where
- 272 sites in United States, Argentina and 27 more
- Volunteers
- 1,461 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01009463
- Testing
- FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
- Where
- 188 sites in United States, Argentina and 13 more
- Volunteers
- 1,626 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed AVA105640.
- Trial name
- NCT00550420
- Testing
- Rosiglitazone XR
- Where
- 70 sites in United States, Austria and 16 more
- Volunteers
- 331 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
The purpose of the study is to investigate the effect of fluticasone furoate/vilanterol Inhalation Powder on arterial stiffness compared with placebo and vilanterol over a 24-week treatment period in subjects with COPD and aortic…
- Trial name
- NCT01336608
- Testing
- Fluticasone Furoate/Vilanterol, Vilanterol
- Where
- 72 sites in United States, Germany and 4 more
- Volunteers
- 446 people
- Sponsor
- GlaxoSmithKline
Peripheral Artery Disease
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.
- Trial name
- EUCLID (NCT01732822)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 776 sites in United States, Argentina and 26 more
- Volunteers
- 13,885 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab
This is an open-label, randomized, parallel group Phase 2A/2B study to evaluate the clinical activity of ASLAN001 in combination with capecitabine compared with lapatinib in combination with capecitabine in patients with HER2…
- Trial name
- NCT02338245
- Testing
- ASLAN001, Lapatinib, Capecitabine
- Where
- 19 sites in Australia, Hong Kong and 5 more
- Volunteers
- 200 people
- Sponsor
- ASLAN Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the efficacy and safety of GSK233705B compared with placebo in subjects with COPD.
- Trial name
- NCT00676052
- Testing
- GSK233705 12.5mcg, GSK233705 25mcg, GSK233705 50mcg
- Where
- 88 sites in United States, Argentina and 12 more
- Volunteers
- 576 people
- Sponsor
- GlaxoSmithKline
Bronchiectasis
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14…
- Trial name
- RESPIRE 2 (NCT02106832)
- Testing
- Ciprofloxacin (BAYQ3939) dry powder for inhalation
- Where
- 207 sites in United States, Argentina and 23 more
- Volunteers
- 521 people
- Sponsor
- Bayer
Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection
Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
To Evaluate the Effects of Ceftazidime-Avibactam and Best Available Therapy in patients with complicated urinary tract infections and complicated intra-abdominal infections.
- Trial name
- NCT01644643
- Testing
- Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole
- Where
- 43 sites in United States, Argentina and 16 more
- Volunteers
- 345 people
- Sponsor
- Pfizer
Focal Infection, Dental
AUGMENTIN™ in Dental Infections
In clinical practice, amoxicillin + clavulanic acid is widely used in the treatment of odontogenic infection. Therefore, this study is designed to generate data to support its use by demonstrating efficacy, safety and…
- Trial name
- AUGDENT (NCT02141217)
- Testing
- Amoxicillin/clavulanate, Clindamycin
- Where
- 15 sites in Malaysia, Philippines and 2 more
- Volunteers
- 472 people
- Sponsor
- GlaxoSmithKline